|
CO5180550A1
(es)
|
1999-04-19 |
2002-07-30 |
Smithkline Beecham Corp |
Inhibidores de fab i
|
|
AR024158A1
(es)
|
1999-06-01 |
2002-09-04 |
Smithkline Beecham Corp |
Compuestos antibacterianos
|
|
DE60017180T2
(de)
|
1999-10-08 |
2005-12-08 |
Affinium Pharmaceuticals, Inc., Toronto |
Fab i inhibitoren
|
|
US6730684B1
(en)
|
1999-10-08 |
2004-05-04 |
Affinium Pharmaceuticals, Inc. |
Fab I inhibitors
|
|
US6762201B1
(en)
|
1999-10-08 |
2004-07-13 |
Affinium Pharmaceuticals, Inc. |
Fab I inhibitors
|
|
CA2444597A1
(en)
|
2001-04-06 |
2002-10-06 |
Affinium Pharmaceuticals, Inc. |
Fab i inhibitors
|
|
AU2003298937A1
(en)
*
|
2002-12-06 |
2004-06-30 |
Affinium Pharmaceuticals, Inc. |
Heterocyclic compounds, methods of making them and their use in therapy
|
|
CA2519429C
(en)
|
2003-03-17 |
2013-08-06 |
Affinium Pharmaceuticals, Inc. |
Pharmaceutical compositions comprising inhibitors of fab i and further antibiotics
|
|
US8450307B2
(en)
*
|
2004-06-04 |
2013-05-28 |
Affinium Pharmaceuticals, Inc. |
Therapeutic agents, and methods of making and using the same
|
|
EP1973902A2
(en)
*
|
2005-12-05 |
2008-10-01 |
Affinium Pharmaceuticals, Inc. |
3-heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
|
|
CA2644809A1
(en)
|
2006-03-02 |
2007-09-07 |
Astellas Pharma Inc. |
17 .beta. hsd type 5 inhibitor
|
|
WO2008009122A1
(en)
|
2006-07-20 |
2008-01-24 |
Affinium Pharmaceuticals, Inc. |
Acrylamide derivatives as fab i inhibitors
|
|
EP2125802A4
(en)
|
2007-02-16 |
2014-08-20 |
Debiopharm Int Sa |
SALTS, PRODRUGS AND POLYMORPHES OF FAB I INHIBITORS
|
|
WO2012064642A1
(en)
*
|
2010-11-08 |
2012-05-18 |
Glaxosmithkline Llc |
Fatty acid synthase inhibitors
|
|
DK2861608T3
(da)
|
2012-06-19 |
2019-06-24 |
Debiopharm Int Sa |
Prodrug-derivater af (e)-n-methyl-n-((3-methylbenzofuran-2-yl)methyl)-3-(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-3-yl)acrylamid
|
|
CN112521369A
(zh)
|
2013-03-13 |
2021-03-19 |
福马治疗股份有限公司 |
用于抑制fasn的化合物及组合物
|
|
BR112018016721A2
(pt)
|
2016-02-26 |
2018-12-26 |
Debiopharm Int Sa |
uso de di-hidrogeno fosfato de {6-[(e)-3-{metil[(3-metil-1-benfofuran-2-iol)metil]amino)-3-xopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)-il}metila e composição farmacêutica para tratamento de infecções bacterianas associadas ao pé diabético
|
|
US11690824B2
(en)
|
2018-04-10 |
2023-07-04 |
The General Hospital Corporation |
Antibacterial compounds
|
|
TWI767148B
(zh)
|
2018-10-10 |
2022-06-11 |
美商弗瑪治療公司 |
抑制脂肪酸合成酶(fasn)
|
|
WO2020092395A1
(en)
|
2018-10-29 |
2020-05-07 |
Forma Therapeutics, Inc. |
SOLID FORMS OF (4-(2-FLUORO-4-(1-METHYL-1 H-BENZO[d]IMIDAZOL-5-YL)BENZOYL) PIPERAZIN-1-YL)(1-HYDROXYCYCLOPROPYL)METHANONE
|
|
LT3923914T
(lt)
|
2019-02-14 |
2023-07-25 |
Debiopharm International S.A. |
Afabicino kompozicija, jos gamybos būdas
|
|
CA3139942A1
(en)
|
2019-06-14 |
2020-12-17 |
Justyna NOWAKOWSKA |
Medicament and use thereof for treating bacterial infections involving biofilm
|